TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06500390

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Examination of temporomandibular joint and masticator muscles
Description: The TMJ and the masticatory muscles were evaluated by the same clinician. Patients described symptoms such as preauricular pain, limited mouth opening, deviation or deflection during mouth opening, and joint sounds. All patients were assessed using Okeson's Muscle and temporomandibular joint examination and treatment outcome form. This form records (for both TMJ) tenderness and pain in the masseter, temporalis, lateral pterygoid, medial pterygoid, sternocleidomastoid, trapezius, splenius capitis, and digastric muscles, as well as maximum interincisal distance, restriction of laterotrusion and protrusive movements, joint sounds, deviation or deflection during mouth opening, and the visual analogue score (VAS) for pain in the TMJ.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Examination of temporomandibular joint and masticator muscles
Description: The TMJ and the masticatory muscles were evaluated by the same clinician. Patients described symptoms such as preauricular pain, limited mouth opening, deviation or deflection during mouth opening, and joint sounds. All patients were assessed using Okeson's Muscle and temporomandibular joint examination and treatment outcome form. This form records (for both TMJ) tenderness and pain in the masseter, temporalis, lateral pterygoid, medial pterygoid, sternocleidomastoid, trapezius, splenius capitis, and digastric muscles, as well as maximum interincisal distance, restriction of laterotrusion and protrusive movements, joint sounds, deviation or deflection during mouth opening, and the visual analogue score (VAS) for pain in the TMJ.
Study: NCT05958901

Intervention type: OTHER
Intervention: pulmonary hypertension
Description: The final outcome observed was a diagnosis of pulmonary hypertension.
Study: NCT05322707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide 80 μg and Formoterol Fumarate Dihydrate 4.5 μg
Description: Inhalation aerosol, 2 actuations orally inhaled twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort, 80 Mcg-4.5 Mcg/Inh Inhalation Aerosol
Description: Inhalation aerosol, 2 actuations orally inhaled twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation aerosol, 2 actuations orally inhaled twice daily
Study: NCT05219500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FPI-2265
Description: Small molecule capable of binding to the domain of PSMA radiolabeled with Ac225
Study: NCT05712460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sisunatovir
Description: Sisunatovir is an orally administered RSV F-protein inhibitor being developed to target viral-host cell fusion for the treatment of adult and pediatric patients with RSV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sisunatovir
Description: Sisunatovir is an orally administered RSV F-protein inhibitor being developed to target viral-host cell fusion for the treatment of adult and pediatric patients with RSV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sisunatovir
Description: Sisunatovir is an orally administered RSV F-protein inhibitor being developed to target viral-host cell fusion for the treatment of adult and pediatric patients with RSV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sisunatovir
Description: Sisunatovir is an orally administered RSV F-protein inhibitor being developed to target viral-host cell fusion for the treatment of adult and pediatric patients with RSV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for sisunatovir
Study: NCT05194969

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wet-to-Dry Dressings
Description: This dressing technique involves moistening a piece of gauze with normal saline or other cleansing solution, placing the moistened gauze on the wound, allowing the gauze to dry, and then removing and replacing the bandage regularly over a period of days to weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Petrolatum with Non-Stick Gauze
Description: This dressing approach involves applying a thick layer of petrolatum to the wound once or twice daily to maintain a moist wound base. After placement of petrolatum, the wound is covered with nonadherent gauze and tape or another bordered dressing.
Study: NCT06097221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CRT-Advance
Description: Psychotherapy with focus on advancing sleep timing, using diaries on sleep and zeitgebers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual in the outpatient psychiatric unit.
Study: NCT04931069

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microbiota analysis
Description: Microbiota analysis will be carried out on different samples: blood, stool and saliva samples will be collected during the surgery, between 5 and 10 days after surgery and at 3 and 6 months after the surgery. Bile, pancreatic and intestinal mucosa samples will only be collected during the surgery.
Study: NCT05460104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Virtual reality sessions with a psychologist (30 minutes per session) once a week for 10 weeks. Work of the psychologist on a virtual environment created for the protocol in partnership with the company.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard care is medical follow-up, no specific psychological care.
Study: NCT05943639

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Cultural Marginality Theory-Based Education
Description: The Cultural Marginality Theory-Based Education program will be held in a face-to-face classroom environment for the students in the experimental group. This training program has been developed based on the concepts of Cultural Marginality Theory. The content and topics of the sessions in the program are arranged according to the conceptual structure and flow of the theory. The training program was created in a certain flow, based on the concepts of recognizing intercultural conflict (2 sessions), marginal living (2 sessions) and alleviating cultural tension (2 sessions). There are 6 sessions in the program and the frequency of sessions is 2 times a week, and each session lasts approximately 45 minutes. The training program will be applied to 33 foreign nursing students in the experimental group.
Study: NCT05358366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Infeccion de Amor (Love Infection)
Description: Love Infection is a filmed dramatized story (telenovela/soap opera) Infección de Amor (IA), or Love Infection - culturally tailored for US Latinas and delivered online. IA is a four-episode HIV prevention telenovela co-created with Latinas and a community-based participatory and interdisciplinary. Participants have one week window to watch the 10-minute episodes from their preferred device and location.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Infeccion de Amor (Love Infection)
Description: Love Infection is a filmed dramatized story (telenovela/soap opera) Infección de Amor (IA), or Love Infection - culturally tailored for US Latinas and delivered online. IA is a four-episode HIV prevention telenovela co-created with Latinas and a community-based participatory and interdisciplinary. Participants have one week window to watch the 10-minute episodes from their preferred device and location.
Study: NCT06270147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine-epinephrine
Description: A total of 60ml of 0.25% Bupivacaine with Epinephrine, divided into 4 aliquots, will be administered laparoscopically at two locations per side along the anterior axillary line between the costal margin and the iliac crest. TAP block timing will be disclosed to the operating surgeon to ensure the correct solution is administered at the appropriate time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-epinephrine
Description: A total of 60ml of 0.25% Bupivacaine with Epinephrine, divided into 4 aliquots, will be administered laparoscopically at two locations per side along the anterior axillary line between the costal margin and the iliac crest. TAP block timing will be disclosed to the operating surgeon to ensure the correct solution is administered at the appropriate time.
Study: NCT06180018

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interrupted sutures
Description: Using interrupted sutures in repair of hypospadias by Snodgrass TIP repair
Study: NCT05435768

Intervention type: DRUG
Intervention: Denosumab
Description: Denosumab 120mg was subcutaneously administered one day before the commencement of radiotherapy or after the PraG treatment every 28 days

Intervention type: DRUG
Intervention: Denosumab
Description: Denosumab 120mg was subcutaneously administered one day before the commencement of radiotherapy or after the PraG treatment every 28 days
Study: NCT06155526

Intervention type: OTHER
Intervention: Activity
Description: patients taking an active rest after swimming sets
Study: NCT06334432

Intervention type: DRUG
Group type: OTHER
Intervention: NUV-1511
Description: Novel small molecule

Intervention type: DRUG
Group type: OTHER
Intervention: NUV-1511
Description: Novel small molecule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUV-1511
Description: Novel small molecule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUV-1511
Description: Novel small molecule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUV-1511
Description: Novel small molecule
Study: NCT05516992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-01 For Injection
Description: Intradiscal injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sham Needle
Description: Sham needle placement
Study: NCT05031520

Intervention type: PROCEDURE
Intervention: Coronary computed tomography angiography (CCTA)
Description: Participants will undergo CCTA. CCTA performed in this study will be technically identical to CCTA that is commonly performed in clinical practice, for which safety profiles are well defined. Guidelines implemented by the National Institutes of Health Radiation Exposure Committee will be followed. Major risks of CCTA include exposure to ionizing radiation, the requirement for intravenous catheter placement and contrast media administration, and side effects of beta-blockers and nitrates that may be used for vasodilation and heart rate control to optimize CCTA image quality.

Intervention type: DRUG
Intervention: Isovue
Description: CCTA requires intravenous catheter placement and the administration of iodinated contrast media (Isovue).

Intervention type: DRUG
Intervention: Nitroglycerin
Description: Medication to promote coronary vasodilation during the CCTA may be administered immediately prior to CCTA to optimize image quality

Intervention type: DRUG
Intervention: Metoprolol
Description: Medication to promote heart rate reduction during the CCTA may be administered immediately prior to CCTA to optimize image quality
Study: NCT05064735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide 2.4 mg
Description: semaglutide subcutaneous (s.c.) 2.4 mg once-weekly or semaglutide placebo once-weekly as adjunct to a reduced-calorie diet and increased physical activity

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: semaglutide 2.4 mg (placebo)
Description: semaglutide subcutanous (s.c.) 2.4 mg once-weekly or semaglutide placebo once-weekly as adjunct to a reduced-calorie diet and increased physical activity
Study: NCT06561919

Intervention type: PROCEDURE
Group type: OTHER
Intervention: bilateral high frequency deep brain stimulation of the subthalamic neucleus combined with best medical treatment according to widely accepted expert consensus paper
Description: Best medical treatment according to widely accepted expert consensus Paper

Intervention type: DRUG
Group type: OTHER
Intervention: best medical treatment for management of impulse control in Parkinson´s disease according to widely accepted expert consensus paper
Description: Best medical treatment according to widely accepted consensus Paper
Study: NCT04727970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tricaprilin
Description: Tricaprilin will be emulsified in infant formula/milk
Study: NCT05226442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban
Description: Argatroban is a synthetic, univalent DTI, that directly binds to the catalytic thrombin binding site exerting its effects

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated heparin
Description: Unfractionated heparin produces its major anticoagulant effect by inactivating thrombin and activated factor X (factor Xa) through an antithrombin (AT)-dependent mechanism.
Study: NCT05831228

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic food products
Description: Participants will be given a ketogenic food product prior to the hyperbaric oxygen exposure.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control: Placebo
Description: Participants will be given a dietary supplement comparator prior to the hyperbaric oxygen exposure.
Study: NCT05895786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06823859
Description: anti-interferon beta therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for PF-06823859
Study: NCT06194825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplontersen
Description: Eplontersen by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eplontersen-matching placebo by subcutaneous injection
Study: NCT05650749

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GPC2 CAR T cells
Description: The GPC2 CAR T investigational product is comprised of autologous human T cells that have been genetically modified to express a GPC2-targeting chimeric antigen receptor (CAR) transgene.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GPC2 CAR T cells
Description: The GPC2 CAR T investigational product is comprised of autologous human T cells that have been genetically modified to express a GPC2-targeting chimeric antigen receptor (CAR) transgene.
Study: NCT05890664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine 0.5 mg (oral) once daily for 90 days. The chemical name for colchicine is (S)-N-(5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9 oxobenzol\[a\]heptalen-7-yl) acetamide.~Colchicine consists of pale yellow scales or powder. It is soluble in water, freely soluble in alcohol, and slightly soluble in ether.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo. Both the active drug and placebo will look similarly. The route and mode of administration is also similar to the active group.
Study: NCT06585657

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: brain visual perception training group
Description: Conduct brain visual perception training through a visual training system to improve binocular visual balance. Train 2 projects per day, each lasting 10 minutes.
Study: NCT05387278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EV-Pure™ and WJ-Pure™
Description: The treatment consists of administration of WJ-Pure™ and EV-Pure™ plus standard care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cryopreservation media plus standard care
Study: NCT05462145

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Globe Pulsed Field System
Description: Ablation and atrial mapping with the Globe Pulsed Field System
Study: NCT04956120

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Citrate Dialysate
Description: Dialysate is generated during dialysate from two concentrates (acid concentrate and bicarbonate concentrate) mixed with treated water. When used, citrate is provided in the acid concentrate. The acid concentrate with citrate is approved for this use by the FDA and will be used according to standard procedures without altered dialysis machine settings.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Citrate Dialysate
Description: Dialysate is generated during dialysate from two concentrates (acid concentrate and bicarbonate concentrate) mixed with treated water. When used, citrate is provided in the acid concentrate. The acid concentrate with citrate is approved for this use by the FDA and will be used according to standard procedures without altered dialysis machine settings.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Dialysate
Description: Dialysate is generated during dialysate from two concentrates (acid concentrate and bicarbonate concentrate) mixed with treated water. The acid concentrate without citrate is approved for this use by the FDA and will be used according to standard procedures without altered dialysis machine settings.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dialysate
Description: Dialysate is generated during dialysate from two concentrates (acid concentrate and bicarbonate concentrate) mixed with treated water. The acid concentrate without citrate is approved for this use by the FDA and will be used according to standard procedures without altered dialysis machine settings.
Study: NCT06459674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrO2 Fit (IMT Trainer)
Description: The device is used four times a week over a period of 8 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PrO2 Fit (IMT Trainer)
Description: The device is used four times a week over a period of 8 weeks.
Study: NCT04825574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avapritinib
Description: avapritinib tablet
Study: NCT06458855

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post radical prostatectomy nerve restoration procedure (PRP-NR)
Description: A somatic to autonomic nerve grafting procedure which will use a nerve graft of ilioinguinal nerve harvested from the inguinal canal to perform a bilateral end to side junction between the dorsal penile nerve and the penile corpora cavernosa
Study: NCT03255408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug Lowering Cerebral Blood Flow (CBF) and Normoxia Sleep
Description: The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Normoxia Exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug Lowering CBF and Intermittent Hypoxia Sleep
Description: The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Intermittent Hypoxia (IH) Exposure

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo and Normoxia Sleep
Description: The study participants will take Placebo and sleep under Normoxia Exposure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Intermittent Hypoxia Sleep
Description: The study participants will take Placebo and sleep under Intermittent Hypoxia (IH) Exposure
Study: NCT06477055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib, 80mg, po, qd.
Study: NCT04586530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory and Attention Adaptation Training (MAAT)
Description: A cognitive-behavioral therapy (CBT) for treatment of chemotherapy-related cognitive dysfunction (CRCD) among cancer survivors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy (ST)
Description: Standard attention control condition therapy for treatment of chemotherapy-related cognitive dysfunction (CRCD) among cancer survivors.
Study: NCT06652243

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SN301A
Description: SN301A is an investigational off-the-shelf CAR NK cell therapy, armed with calibrated release (cr)IL15, designed to selectively target and treat GPC3 expressing advanced hepatocellular carcinoma.~Subjects will receive lymphodepletion pretreatment (Fludarabine/Cyclophosphamide), three SN301A intravenous infusions in a cycle (D0, D7, D14), with each subject receiving a maximum of 3 cycles.
Study: NCT05653492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulforaphane
Description: Dosing study one to four 30 mg/d tablets depending on weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulforaphane
Description: Dosing study one to four 30 mg/d tablets depending on weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulforaphane
Description: Dosing study one to four 30 mg/d tablets depending on weight
Study: NCT06596369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal cord stimulation
Description: Continuous, sub motor threshold stimulation is delivered through surface electrodes placed over the cervical spine region.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper extremity rehabilitation
Description: Using the ReJoyce system individuals will engage in upper extremity rehabilitation.
Study: NCT06598046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone and capecitabine
Description: Utidelone: intravenous capecitabine: oral
Study: NCT06590922

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group using new oropharyngeal airway (experimental group)
Description: Before anesthesia induction, study participants in the experimental group received 5-6L/min oxygen for about 1min through an endoscopic bite oxygen supply device, and anesthesia induction was administered with propofol 3mg/kg and sufentanil 7μg.Sufentanil was given at the beginning of pre-oxygen inhalation, and propofol was given 1min later. When participants achieved sufficient sedation (about BIS40), they were placed into the oropharyngeal airway through the endoscopic bite and began gastroscopy.Anesthetic maintenance was administered with a continuous pump of 5mg/kg·h propofol until completion of the examination.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The conventional endoscopic biting group (control group)
Description: Prior to induction of anesthesia, control study participants inhaled 5 to 6L/min of oxygen through a nasal catheter for approximately 1 minute.Anesthesia was induced by propofol 3mg/kg and sufentanil 7μg.Sufentanil was given at the beginning of pre-oxygen inhalation, and propofol was given 1min later. The endoscopic procedure began when the study participants reached sufficient sedation (about BIS40) and the ordinary endoscopic bite group reached sufficient sedation.Anesthetic maintenance was administered with a continuous pump of 5mg/kg·h propofol until completion of the examination.